Should Biosimilars Be Cheap? Sponsors Aren't So Sure
Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts.
You may also be interested in...
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.